

Poland

Tuberculosis profile

Population 2015

39 million

Estimates of TB burden*, 2015	Number (thousands)	Rate (per 100 000 population)
Mortality (excludes HIV+TB)	0.54 (0.52–0.57)	1.4 (1.4–1.5)
Mortality (HIV+TB only)	0.019 (<0.01–0.093)	0.05 (0–0.24)
Incidence (includes HIV+TB)	7.2 (6.2–8.3)	19 (16–21)
Incidence (HIV+TB only)	0.14 (0.11–0.18)	0.37 (0.28–0.46)
Incidence (MDR/RR-TB)**	0.07 (0.049–0.091)	0.18 (0.13–0.24)

Estimated TB incidence by age and sex (thousands)*, 2015			
	0-14 years	> 14 years	Total
Females	0.28 (0.18–0.39)	2 (1.3–2.8)	2.3 (1.4–3.2)
Males	0.26 (0.18–0.35)	4.6 (3.6–5.6)	4.8 (3.8–5.9)
Total	0.55 (0.42–0.68)	6.6 (6–7.2)	7.2 (6.2–8.3)

TB case notifications, 2015	
Total cases notified	6 430
Total new and relapse	6 237
- % tested with rapid diagnostics at time of diagnosis	12%
- % with known HIV status	<1%
- % pulmonary	94%
- % bacteriologically confirmed among pulmonary	76%

Universal health coverage and social protection	
TB treatment coverage (notified/estimated incidence), 2015	87% (75–100)
TB patients facing catastrophic total costs	
TB case fatality ratio (estimated mortality/estimated incidence), 2015	0.08 (0.07–0.09)

TB/HIV care in new and relapse TB patients, 2015		Number	(%)
Patients with known HIV-status who are HIV-positive			
- on antiretroviral therapy			

Drug-resistant TB care, 2015			
	New cases	Previously treated cases	Total number***
Estimated MDR/RR-TB cases among notified pulmonary TB cases			60 (42–79)
Estimated % of TB cases with MDR/RR-TB	0.66% (0.42–0.98)	3.7% (2.1–5.9)	
% notified tested for rifampicin resistance	65%	63%	4 177
MDR/RR-TB cases tested for resistance to second-line drugs			9
Laboratory-confirmed cases		MDR/RR-TB: 44, XDR-TB: 3	
Patients started on treatment ****		MDR/RR-TB: 34, XDR-TB:	

Treatment success rate and cohort size		
	Success	Cohort
New and relapse cases registered in 2014	58%	6 500
Previously treated cases, excluding relapse, registered in 2014	49%	149
HIV-positive TB cases, all types, registered in 2014		
MDR/RR-TB cases started on second-line treatment in 2013	22%	46
XDR-TB cases started on second-line treatment in 2013	0%	1

TB preventive treatment, 2015	
% of HIV-positive people (newly enrolled in care) on preventive treatment	
% of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment	

TB financing, 2016	
National TB budget (US\$ millions)	


* Ranges represent uncertainty intervals

** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin

*** Includes cases with unknown previous TB treatment history


**** Includes patients diagnosed before 2015 and patients who were not laboratory-confirmed

(Rate per 100 000 population per year)




— Mortality (excludes HIV+TB)

(Rate per 100 000 population per year)




— Incidence
— Notified (new and relapse)
— Incidence (HIV+TB only)

Notified cases by age group and sex, 2015



Treatment success rate (%)



— New and relapse
— Retreatment, excluding relapse
— HIV-positive — MDR/RR-TB — XDR-TB